GlassScriptPhysician profile
Ahmed Elsharkawi
NPI 1861456378
$19,109.55
in general payments reported to CMS, 2019-2025
61 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $890 · 2021: $1,435 · 2022: $1,839 · 2023: $8,967 · 2024: $3,437 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,000 · Food and Beverage: $4,744 · Travel and Lodging: $2,966 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,000.00 |
| Food and Beverage | $4,744.37 |
| Travel and Lodging | $2,966.44 |
| Education | $167.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $8,146.84 | 2020-2023 | Krystexxa |
| Csl Behring | $1,638.18 | 2024 | |
| Mallinckrodt Hospital Products INC. | $1,053.94 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $953.66 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $730.75 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Vifor Pharma, INC. | $571.32 | 2019-2025 | Veltassa |
| Novo Nordisk INC | $488.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $480.03 | 2019-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $461.59 | 2023-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $397.31 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $375.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $360.60 | 2019-2025 | |
| Abbvie INC. | $357.52 | 2020-2025 | |
| Fresenius USA Marketing, INC. | $323.09 | 2019-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $284.04 | 2019-2024 | Jardiance, Mounjaro |
Show all 60 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Elsharkawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.